GlassScriptPhysician profile
Hashmi Rafeek
NPI 1134372659
$1,797.92
in general payments reported to CMS, 2019-2025
13 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $212 · 2021: $966 · 2022: $185 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $152.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $355.07 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $305.75 | 2021-2022 | |
| Astellas Pharma US INC | $287.24 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $217.79 | 2019-2022 | |
| Allergan, INC. | $113.31 | 2019-2020 | |
| Insmed, INC. | $94.59 | 2022-2025 | Arikayce |
| Viiv Healthcare Company | $90.43 | 2020-2022 | |
| Gilead Sciences, INC. | $84.43 | 2019-2021 | |
| Tetraphase Pharmaceuticals, INC. | $82.85 | 2019 | |
| Melinta Therapeutics, LLC | $77.18 | 2021 | |
| Aimmune Therapeutics, INC. | $36.80 | 2025 | Vowst |
| Shionogi INC | $34.79 | 2025 | Fetroja |
| Theratechnologies INC. | $17.69 | 2025 | Egrifta, Trogarzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hashmi Rafeek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.